Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Quillivant Oral Suspension XR
Quillivant · 1 trial · 1 indication
The SKAMP scale measures the manifestations of attention deficit hyperactivity disorder (ADHD) using an independent observer rating of the participant's impairment in classroom observed behaviors. SKAMP combined score is comprised of 13 items (including subscales: attention with items 1-4, deportment with items 5-8, quality of work with items 9-11 and compliance with items 12-13). The SKAMP composite score was obtained by summing up each item score where each item is rated on a 7-point impairment scale (0=normal to 6=maximal impairment) for a total possible combined score of 0 to 78; where higher score signified worst impairment.
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | - |
| Comparator | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Quillivant Oral Suspension XR | DRUG | Oral Suspension 25mg/5mL; 20-60 mg/day |
| Placebo | DRUG | Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day |
Inclusion Criteria: * Male or female from 6 to 12 years of age at the time of screening, inclusive. * Diagnosis of ADHD by a Psychiatrist, Psychologist, Developmental Pediatrician, or a Pediatrician meeting diagnostic criteria for ADHD (DSM-IV). A Schedule for Affective Disorders and Schizophrenia ...
Quillivant is used to treat Attention Deficit Hyperactivity Disorder (ADHD). It is an oral suspension formulation developed for this psychiatric condition. The clinical program enrolled patients aged 6 years and older in the United States.
Quillivant is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the company behind the Quillivant Oral Suspension XR product.
Quillivant has been studied in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently active. The completed study was a randomized, double-blind, placebo-controlled trial conducted in the United States.
Quillivant was evaluated in the Phase 3 trial NCT00904670, titled Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD). The trial is completed and enrolled 45 participants aged 6 years and older, with both sexes eligible and no healthy volunteers.
Yes, Quillivant is also known as Quillivant Oral Suspension XR. Both names refer to the same extended-release oral suspension product developed by Pfizer for the treatment of Attention Deficit Hyperactivity Disorder.
The Quillivant Phase 3 trial NCT00904670 was a randomized, double-blind, placebo-controlled study. It enrolled 45 participants with Attention Deficit Hyperactivity Disorder in the United States, included patients aged 6 years and older of all sexes, and did not enroll healthy volunteers.